ImpediMed Limited (IPD) Q4 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you, McGregor. Good morning. Thank you for joining us to discuss the Q4 fiscal year 26 results. I'm pleased to be here with McGregor Grant, our CFO. We'll be referring to the 4C quarterly activity report and presentation we lodged this morning with the ASX. After our remarks, we'll be answering questions. You can lodge questions throughout the presentation using the Investor Hub Q&A function. I'll begin on slide three with an overview of the agenda for today's call. I'm going to start with a business overview, including key highlights, and take you through an update on each of the three business segments. I'll then hand over to McGregor to present the financials. And I'll then finish with some closing remarks and cover our outlook for this quarter before opening up for Q&A. So if we turn to slide five, I know many of you will have only had a chance to briefly read the 4C Activities Report, but you'll notice we made a step change here from previous reports in that I very purposefully added CEO commentary, both within the report and in the concluding notes. I understand the market is keen to get my takes on the business, and you'll see and hear those themes in the report, in this webinar, and in the Q&A and meetings with you that follow. So number one, a strong foundation. We start from a genuine strong foundation, FDA cleared, TGA cleared, CE marked digital health platform. Now paired with a new executive leadership team focused on turning that technology into disciplined commercial execution. We're playing in three segments that are all moving in our direction. Cancer survivorship shift toward longer term patient care, the growing clinical and economic burden of heart failure readmissions, and the GLP-1 driven need to actually measure, not just assume muscle ma...